NEW YORK, NY -- (Marketwire) -- 01/09/12 -- Stem Cell stocks -- particularly companies focused on adult stems cells -- have performed well of late. Earlier this month Goldman Sachs noted the potential upside of Pluristem Therapeutics -- noting that the company does not use the highly controversial embryonic stem cells. The remark from the analyst firm helped drive shares of similar companies that use adult stem cells. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. (NASDAQ: ASTM) and Cytori Therapeutics (NASDAQ: CYTX). Access to the full company reports can be found at:
www.paragonreport.com/ASTM
www.paragonreport.com/CYTX
Cytori provides patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. Last month Cytori filed its Investigational Device Exemption (IDE) application to begin a clinical trial of the Company's Celution System for chronic myocardial ischemia (CMI).
The company is currently using fat cell-derived stem and regenerative cells to develop treatments for heart disease and reconstructive surgery. According to a recent article from Reuters, to treat heart attack, a small amount of fat tissue is removed shortly after the heart attack, stem and regenerative cells are separated and concentrated and the cells are infused into the coronary artery to increase blood flow.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Aastrom Biosciences' proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. This year, the company is set to start a Phase III trial of its treatment for critical limb ischemia (CLI), a severe form of peripheral artery disease. Aastrom uses cells derived from a patient's own bone marrow. The company is also conducting Phase II trials of the drug in patients with dilated cardiomyopathy, an end-stage form of heart failure, Reuters explains.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
